Himanshu Sethi
0000-0002-5787-8901
Natera Inc
34 papers found
Refreshing results…
370P Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Factors Influencing Background Cell-Free Dna Levels: Implications for Donor Derived Cell-Free Dna Assessment in Transplant Patients
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
The effect of surgical trauma on circulating free DNA levels in cancer patients—implications for studies of circulating tumor DNA
Characterization of clonal hematopoiesis of indeterminate potential mutations from germline whole exome sequencing data.
Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.
Analysis of circulating tumour DNA for early relapse detection in stage III colorectal cancer after adjuvant chemotherapy
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma
Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence
Abstract 4542: Analytical validation of the SignateraTM RUO assay, a highly sensitive patient-specific multiplex PCR NGS-based noninvasive cancer recurrence detection and therapy monitoring assay
Global identification of noncoding RNAs in Saccharomyces cerevisiae by modulating an essential RNA processing pathway
Identification of transcribed sequences in Arabidopsis thaliana by using high-resolution genome tiling arrays
Missing publications? Search for publications with a matching author name.